Aardvark Therapeutics (NASDAQ:AARD) CFO Acquires $43,200.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Nelson Sun bought 3,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was purchased at an average cost of $14.40 per share, with a total value of $43,200.00. Following the completion of the purchase, the chief financial officer directly owned 108,484 shares in the company, valued at approximately $1,562,169.60. This trade represents a 2.84% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Aardvark Therapeutics Stock Down 7.6%

AARD stock opened at $14.43 on Monday. Aardvark Therapeutics, Inc. has a twelve month low of $4.88 and a twelve month high of $19.58. The company has a market cap of $314.14 million and a P/E ratio of -6.81. The business has a fifty day moving average of $11.93 and a 200-day moving average of $11.73.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Institutional Investors Weigh In On Aardvark Therapeutics

Several hedge funds have recently bought and sold shares of the company. Walleye Capital LLC acquired a new position in shares of Aardvark Therapeutics in the 1st quarter valued at $88,000. Braidwell LP acquired a new position in Aardvark Therapeutics in the first quarter valued at about $3,755,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Aardvark Therapeutics in the first quarter worth about $1,878,000. Cormorant Asset Management LP acquired a new stake in shares of Aardvark Therapeutics during the first quarter worth about $6,009,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Aardvark Therapeutics during the 1st quarter valued at about $153,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Bank of America cut their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, August 28th. Royal Bank Of Canada dropped their target price on shares of Aardvark Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, November 14th. BTIG Research started coverage on Aardvark Therapeutics in a research note on Friday, November 7th. They issued a “buy” rating and a $26.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Aardvark Therapeutics in a research report on Friday, November 14th. Finally, Stifel Nicolaus started coverage on Aardvark Therapeutics in a report on Monday, September 29th. They issued a “buy” rating and a $24.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Aardvark Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $32.44.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.